Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Abstract

The change in schedule of paclitaxel from once every 3 weeks to a more frequent administration significantly improved the ability to eradicate invasive cancer in the breast and lymph nodes.

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

“…Severe side effects were infrequent. In general, the toxicity profile of the three regimens was similar to that shown in previously reported phase II studies with these regimens in patients with MBC [3][4][5][6][7][8][9]. The combination of gemcitabine and docetaxel was more myelotoxic than the other two regimens, while paclitaxel containing combinations were more neurotoxic.…”

“…Three of them, paclitaxel and carboplatin [3,4], docetaxel and gemcitabine [5,6] and weekly paclitaxel [7][8][9] have demonstrated significant activity and manageable toxicity. Furthermore, the first of these combinations was found to be effective in a phase III trial [10], when compared to the combination of paclitaxel and epirubicin, in terms of overall response rate (ORR), survival and quality of life (QoL).…”

Imaging and dosimetry of 99mTc EC annexin V: Preliminary clinical study targeting apoptosis in breast tumors

“…on long-term prognosis have still to be determined (4,5). We reported the preliminary analysis of a randomized neo-adjuvant protocol comparing a weekly schedule vs. an every three-week schedule of paclitaxel (5).…”

“…We reported the preliminary analysis of a randomized neo-adjuvant protocol comparing a weekly schedule vs. an every three-week schedule of paclitaxel (5). The results showed a significant difference in pCR between the weekly schedule (pCR= 30.8%) compared to the every 3 weeks (pCR=11.4%).…”

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

“…Paclitaxel remains a standard treatment for a variety of cancers, including lung, breast, head and neck, and ovary, and may be administered weekly to reduce haematological toxicity either alone or in combination with other anti-tumour agents on an every-week (Green et al, 2005;Le et al, 2006;Schuette et al, 2006;Yamamoto et al, 2006) or a weekly for 3 weeks monthly schedule (Perez et al, 2005;Yeh et al, 2005;Ramalingam et al, 2006;Stathopoulos et al, 2007). Several tumour types that display sensitivity to paclitaxel also show activation of the PI3-kinase/Akt/mTOR signalling pathway (Shayesteh et al, 1999;Hu et al, 2000;Perez-Tenorio et al, 2002;David et al, 2004;Samuels et al, 2004;Saal et al, 2005).…”